Ultima Genomics to provide low-cost $100 genome sequencing

The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

Drugs & Targets

NeoGenomics launches NGS assay for AML

AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.

October 11, 2024

Vol.50 No.38

Drugs & Targets

Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics

Myriad Genetics Inc. and Ultima Genomics Inc. join to explore Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its Lab of the Future facility in South San Francisco.

October 11, 2024

Vol.50 No.38

In Brief

John Ashton named associate director for shared resources at Wilmot Cancer Institute

John M. Ashton, associate professor in the department of biomedical genetics, has been promoted from assistant director to associate director of shared resources at the University of Rochester’s Wilmot Cancer Institute.

September 13, 2024

Vol.50 No.34

Drugs & Targets

Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities

Labcorp announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing clinical applications, including molecular residual disease in patients with early-stage solid tumor cancers.

August 02, 2024

Vol.50 No.31

Ultima Genomics to provide low-cost $100 genome sequencing

YOU MAY BE INTERESTED IN

The Human Tumor Atlas Network charts the roadmap for advancing spatial omics

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

NeoGenomics launches NGS assay for AML

Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics

John Ashton named associate director for shared resources at Wilmot Cancer Institute

Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities

Renew today!

Subscriber content

Never miss an issue!

Login